Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW766944 · 1 trial · 1 indication
Sputum was collected according to the Hargreave/Nair Sputum Induction procedures.Each site performed their sputum analysis locally. Sputum induction for eosinophils was carried out at screening and Day 10. The absolute cell count of eosinophils in induced sputum has been presented.
Sputum was collected according to the Hargreave/Nair Sputum Induction procedures. Each site performed their sputum analysis locally. At Visit 5 (Day 17), all participants were given 30 mg oral daily prednisone for 5 days and participants returned to clinic at a Post Oral Prednisone Visit (Visit 6) at Day 22. Sputum induction for eosinophils was carried out at screening and Post Oral Prednisone Visit (Day 22). The absolute cell count of eosinophils in induced sputum has been presented.
Sputum was collected according to the Hargreave/Nair Sputum Induction procedures. Each site performed their sputum analysis locally. Sputum induction for eosinophils was carried out at screening and Day 10. Percentage count of eosinophils in induced sputum has been presented.
Sputum was collected according to the Hargreave/Nair Sputum Induction procedures. Each site performed their sputum analysis locally. At Visit 5, all participants were given 30 mg oral daily prednisone for 5 days and participants returned to clinic at a Post Oral Prednisone Visit (Visit 6) at Day 22. Sputum induction for eosinophils was carried out at screening and Post Oral Prednisone Visit (Day 22). Percentage count of eosinophils in induced sputum has been presented.
| Arm | Type | Description |
|---|---|---|
| GW766944 | ACTIVE_COMPARATOR | This is the active drug (GW766944) |
| Placebo | PLACEBO_COMPARATOR | Placebo Arm. |
| Name | Type | Description |
|---|---|---|
| GW766944 | DRUG | Drug: GW766944 (Active Drug Treatment) |
| Placebo | OTHER | This is placebo to match. |
Inclusion Criteria: * Physician diagnosis of asthma (\>12% improvement in FEV1 with a bronchodilator or PC20 methacholine less than 8 mg/ml) documented within the past 2 years. * Males and females aged ≥18-75 years inclusive. * A female subject is eligible to participate if she is of: * Non-childbe...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
GW766944 is an investigational oral small molecule developed by GSK plc for the treatment of asthma. It was studied in a Phase 2 clinical trial in adults with asthma. It is not an approved therapy and remains in clinical development.
GW766944 is developed by GSK plc, which trades under the ticker GSK. The compound was evaluated in a company-sponsored Phase 2 study in asthma.
GW766944 has completed a Phase 2 clinical trial in asthma. No active trials are currently listed for this asset. It is an investigational drug and has not been approved for any indication.
GW766944 was studied in one completed Phase 2 trial, NCT01160224, titled Oral GW766944 (Oral CCR3 Antagonist). The trial enrolled 60 adults with asthma in Canada and used a randomized, double-blind, placebo-controlled design.
Yes, the Phase 2 trial of GW766944 in asthma was biomarker-selected, meaning participants were chosen based on a specific biomarker. The study enrolled 60 adults and was randomized, double-blind, and placebo-controlled.